ATHENS, Greece--(BUSINESS WIRE)--Dec. 22, 2005--Acrongenomics, Inc. (OTCBB:AGNM) a publicly traded research and development nanobiotechnology company pioneering the development of uniquely advanced nano-molecular diagnostics, today announced the closing of the 1,000,000 share private placement financing at $4.00 per share as of Friday December 16th 2005. Acrongenomics will use the net proceeds for the ongoing development of the Nano-JETA platform as well as general corporate purposes.
